Good efficacy and safety of vedolizumab in Crohn's disease and ulcerative colitis in a real-world scenario

Therapeutic Advances in Gastroenterology
Fabiana ZingoneEdoardo Vincenzo Savarino

Abstract

Data on vedolizumab (VDZ) use in inflammatory bowel disease (IBD) patients are still limited. We aimed to assess the effectiveness and tolerability of VDZ in a real-life clinical scenario. We retrospectively collected data of all consecutive IBD patients who started VDZ from September 2016 to December 2018 at our IBD Unit of the University Hospital of Padua and strictly followed them for 1 year. Clinical benefit (rate of clinical steroid-free remission plus clinical response), endoscopic and histological responses were evaluated over 1 year. A total of 117 patients who started VDZ for Crohn's disease (CD) and ulcerative colitis (UC) were included in the main analysis (69 CD patients, 48 UC patients). We obtained a clinical benefit in 68.1%, 68.1% and 59.4% of CD patients and in 68.7%, 54.2% and 54.1% of UC patients after induction, and at 30 weeks and 52 weeks, respectively. After 1 year, endoscopy response was observed in 47% of CD and 38.2% of UC patients, while the histological response was 19.6% and 23.5%, respectively. Finally, we found that 20.5% of patients needed treatment optimization, with 33.3% of them failing to respond despite this action. No deaths or serious adverse events requiring hospitalization were observed....Continue Reading

References

Feb 22, 2012·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Christina HaAsher Kornbluth
Aug 24, 2013·The New England Journal of Medicine·William J SandbornUNKNOWN GEMINI 2 Study Group
Aug 20, 2015·Inflammatory Bowel Diseases·Edward SheltonVijay Yajnik
Dec 19, 2015·Journal of Crohn's & Colitis·Emily E VivioMatthew A Ciorba
Jan 30, 2016·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Alessandro ArmuzziUNKNOWN GIVI (Gruppo Italiano su Vedolizumab nelle IBD) Group
Feb 20, 2016·Gut·Jean-Frédéric ColombelBrian G Feagan
Oct 19, 2016·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Aurelien AmiotUNKNOWN Groupe d'Etude Therapeutique des Affections Inflammatoires du tube Digestif
Jun 15, 2016·The American Journal of Gastroenterology·Parambir S DulaiJean-Frederic Colombel
Sep 19, 2016·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Brian G FeaganMichael Smyth
Apr 4, 2017·Journal of Crohn's & Colitis·Maja NomanGert Van Assche
May 20, 2017·Clinical Pharmacokinetics·Maria RosarioIrving Fox
Jun 9, 2017·Alimentary Pharmacology & Therapeutics·A AmiotUNKNOWN OBSERV-IBD study group and the GETAID
Aug 26, 2017·Frontline Gastroenterology·Mark A SamaanPeter M Irving
Oct 28, 2017·Journal of Crohn's & Colitis·Tal EngelUri Kopylov
Feb 28, 2018·Digestive Diseases and Sciences·Mark FleisherBrian G Feagan
Mar 27, 2018·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Fabio Salvatore MacalusoAmbrogio Orlando
Jun 23, 2018·World Journal of Gastroenterology : WJG·Maria Lia Scribano
Jun 6, 2019·Alimentary Pharmacology & Therapeutics·Aurelien AmiotUNKNOWN OBSERV-IBD study group, the GETAID
Jun 9, 2019·Gastroenterology·Mark LöwenbergGeert D'Haens
Dec 31, 2019·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Vincenzo VillanacciAlessandro Armuzzi

❮ Previous
Next ❯

Software Mentioned

STATA11
GEMINI

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.